FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2260-2261 November 23, 2006 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Johnston, S. L. PubMed Citation

To the Editor: In their study of the efficacy of telithromycin in patients with acute asthma exacerbations, Johnston et al. (April 13 issue)¹ discount the risk of acute liver failure. They do not mention that in 2001 an advisory committee of the Food and Drug Administration (FDA) voted against approval of telithromycin primarily because of concern about hepatotoxicity.² In response, the drug's manufacturer conducted a trial involving 24,000 patients that was plagued by issues of fraud and data integrity of such magnitude that the FDA could not use the results to support approval.²

Lacking reliable data to counter the advisory . . . [Full Text of this Article]

This article has been cited by other articles:

• Ohmer, J., Miller, J. W, Sasich, L. D (2007). Accessing FDA Approval Packages and Briefing Documents. The Annals of Pharmacotherapy 41: 2071-2072 [Full Text]  
• Ross, D. B. (2007). The FDA and the Case of Ketek. NEJM 356: 1601-1604 [Full Text]